A phase two study investigating the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective front-line treatment for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia.
Myelodysplastic syndrome (MDS) is a type of cancer in which the bone marrow does not make enough healthy blood cells, resulting in abnormal (blast...
A study investigating the potential of the antifibrotic compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in...
Although primary uveal melanoma can be effectively treated with radiation or surgery, patients with metastatic disease — or those at high...
By reducing investments in medical research, any short-term savings will prove to be very costly in the long run — and not just financially. That was the crux of the argument made by Ethan Dmitrovsky, M.D., in an opinion piece recently published in the Pittsburgh Post-Gazette.
“In recent years, America has reduced its commitment to developing new treatments and cures. If we continue down this path, short-term savings will be eclipsed...A genetic misfire called the 3q26.2 amplicon can cause real havoc. In fact, it’s among the most frequent chromosomal aberrations seen in many...
Biotech companies Intrexon and ZIOPHARM Oncology have licensed unique MD Anderson immunotherapy technology, creating an...